Anti-Diabetic Pharmaceuticals Market in India 2012

1
I
Anti-Diabetic Pharmaceuticals Market - India
March 2012
2
Executive Summary
Global Market of Anti-diabetic pharmaceuticals is
expected to growth at a CAGR of X for 2010
- 2015 period
Anti-diabetic pharmaceuticals market in India is
valued at INR xx units in 20--
Market
Market is expected to grow at a CAGR of m from
20-- to 20--
Anti-diabetes therapeutic segment is the second
fastest growing segment, after oncology
Drivers
Challenges
Price regulation in insulin market
Increase in the number of diabetic
Use of complementary and alternative
patients
Drivers and
medicines
Challenges
Introduction of newer and better drugsIncreasing
aging population
Maintainence of healthy lifestyle to
avoiddiabetes
Comprehensive health insurancespolicies covering
diabetes
Drug
Phases of clinical trial
Regulation and
Approval and licensing of drugs
Patents
Patents
Public Companies
Private Companies
Company A
Company G
Company B
Company H
Competition
Company C
Company I
Company D
Company J
Company E
Company F
2
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT
3
Introduction
Market Overview
Drivers Challenges
Government Initiatives
Market Value Chain, Regulation andPatents
Competition
Strategic recommendation
3
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT
4
Indias diabetes market is poised to grow over
the coming
years
Indian Market - Overview
Market Size and Growth
India is considered to be one of the most
lucrative diabetes markets in the world
INR bn y F
Anti-diabetics represent the second fastest
growing
40
E
therapeutic segment among all the segments
,afteroncology
C D
30 A B
Market is expected to grow from INR A bn to INR
F bn in 20--, at a CAGR of y
20
Biguanides, Gliclazide, Gliclazide with
metformine, Rosiglitazone and Pioglitazone are
the top selling drugs
10
0
in Indian market
20-- 20--e
20--e 20--e 20--e 20--e
Human Mixard 30/70 is the largest selling
insulin in Indian market
It showed largest growth among the top 10 brands
in IndianPharmaceutical market
Growth in therapeutic segments(2010)
Market Segmentation
DrugsInsulin
0 5 10 15 20 25 30 35

oncology diabetes
ab
X 1
Y 2
CVSCNS
c de
X 2
Y 1
respiratory pain
f
gastro
g
anti-infectives h
Source
4
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT
5
Drivers Challenges
Challenges
Price regulation in insulin market
Drivers
Increase in the number of diabeticpatients
Competition from complementary andalternative
medicines
Introduction of newer and betterdrugs
Maintainence of healthy lifestyle toavoid
diabetes
Increasing aging population
Increase in health insurances
5
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT
6
Various initiatives taken by the government is
providing a
boost to this market
ICDC ,registered under Planning Commission,
Government of India, is the only organisation
inIndia providing doorstep diabetes care
ICDC implements National Doorstep Diabetes
Identification and follow-up programme
through Grass Root Level NGOs all over India
Indian Council for Diabetic Care
ICDC affiliates NGOs as Partner Organisation
and reach people who are suffering with Diabetes
and help them to control diabetes and live
without any complications
ICDC provides free glucometer and 100 Strips to
the NGOs to start identifying the diabetes
patients even in villages
ICDC is making efforts to provide medical
insurance to the diabetes patients through
Government of India as in the case of family
planning insurance scheme
National Programme for prevention and Control of
Diabetes, Cardiovascular diseases and Stroke
(NPCDCS) was started in 2008,with the objective
of prevention, diagnosis and early
management of diabetes
NPCDCS
It is already being implemented in 100 most
backward and remote districts spread across 21
states
Indian Government plans to extend this
programme to all the 650 districts of the country
under the 12th
five year plan
National Rural Health Mission is providing
services for diabetes care in rural India
NRHM
Seeks to provide effective healthcare to rural
population throughout the country with
special focus on 18 states
Source
6
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT
7
Major Private Companies - Summary
PAT
1,000
Size of the Bubble represents Total Assets in
INR XX
A
0
-1,000
-2,000
B
-3,000
-4,000
-5,000
-6,000
-7,000
-8,000
-9,000
C
-10,000
Revenue2,000,000 2,500,000 3,000,000 3,500,000
-11,000
-500,000
0 500,000 1,000,000 1,500,000
A B C
7
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT
8
Public Domestic Company - A Company (1/3)
Company Information
Offices and Centres - India
X Road
Corporate Address
Bangalore
Tel No.
91 xx xxxxx xxxxx
Fax No.
91 xx xxxxx xxxxx
Website
www.ppp.com
Year of Incorporation
19--
Ticker Symbol
xxxxxx
Stock Exchange
NNN
Products and Services
City A
Head Office
Category
Products/Services
Key People
CVD, CNS, respiratory, dermatology,
Pharmaceutical orthopedics, nutritional, urology,
anti-
Name Designation
infectives
Person M Founder
Infectious diseases, metabolic diseases,inflammat
ory/respiratory diseases, andoncology
MoleculeDevelopment
Person N CFOPerson O Head
Person Q
President
Source
8
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT
9
Public Domestic Company - A Company (2/3)
Financial Snapshot
Key Ratios
Particulars
y-o-y change 20-- 20--
20-- 20--
RevenueINR mn
Revenue Profit
Profitability Ratios
INR mnProfit / Loss
q
pn0
Operating MarginNet Margin
t r
s s
Profit Before Tax MarginReturn on Equity
r p
q m n o
Return on Capital EmployedReturn on Working
CapitalReturn on Assets
t
-m
0
20-- 20-- 20-- 20--
Financial Summary
Return on Fixed Assets
Cost Ratios
The company incurred a net loss of INR xx mn in
FY 20--, as compared to net profit of INR yy mn
in FY 20--
Operating costs ( of Sales)Administration costs
( of
Sales)
The company reported total income of INR xx bn
in FY 20--, registering an increase of yy per
cent over FY 20--
Interest costs ( of Sales)
Liquidity Ratios
The company earned an operating margin of x per
cent in FY 20-- a decrease of y percentage
points over FY 20--
Current RatioCash Ratio
The company reported debt to equity ratio of x
in FY 20--, an increase of y per cent over FY
20--
Leverage Ratios
Debt to Equity RatioDebt to Capital
RatioInterest Coverage Ratio
Financial Summary
Indicators Present Value
Efficiency Ratios
Market Capitalization (INR) X mn
Fixed Asset TurnoverAsset Turnover
Total Enterprise Value (INR) Y mn
Current Asset TurnoverWorking Capital Turnover
EPS (INR) Z mn
PE Ratio (Absolute) A
Capital Employed Turnover
Source
Improved
Decline
9
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT
10
Public Domestic Company - A Company (3/3)
Key Business Segments
Key Geographic Segments
m n o
x y z
x
x x x
xx x x
y y
y
y
y z
z z z
z y z y z
z y
20--
20--
20--
20--
20--
20--
20--
20--
Key Recent Developments
Description
News
Company A is an integrated research based
company that produces a wide range of generic
medicines
Overview
Serves customers in over 100 countries with
manufacturing facilities in several countries
Launched Drug M for the treatment of diabetes
Diabetes Management
Also manufactures Insulin N under its Diabetes
management segment
Is making consistent effort for continual
improvement in rural areas with respect to
accessibility of medicines
Key Initiatives
Source
10
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT
11
For more details about the report visit
http//www.bharatbook.com/medical-devices-market-r
esearch-reports/adonis-medical-systems-pvt-ltd-com
pany-profile-2011.html
http//www.bharatbook.com/healthcare-market-resear
ch-reports/anti-diabetic-pharmaceuticals-market-in
-india-2012.html
Bharat Book Bureau Phone [phone],
27810773 Fax [phone] E-mail
info_at_bharatbook.com Website www.bharatbook.com